Parkinson's disease (PD) is the most common neurodegenerative movement disorder and the classic clinical-neuropathological features of PD have been well established, including many aspects of the morphology and distribution the filamentous hallmark intraneuronal inclusions of PD known as Lewy bodies (LBs). Nonetheless, the mechanisms underlying brain degeneration in PD are unknown, while only partially effective symptomatic treatments for PD are available, and there are no known therepeutic interventions that are able to prevent PD or block or retard the progression of this relentless disorder. However, dramatic new insights into pathobiology of PD have emerged recently with recognition that alpha-synuclein abnormalities play a role in the onset and/or progression of PD. Moreover, continuing advances in this new research arena provide fresh research opportunities to advance understanding of PD, and these novel breakthroughs will accelerate discovery of more effective therapies for PD.